Ceregene Scores $11.5M

San Diego-based biopharmaceuticals firm Ceregene announced this morning that it has raised $11.5M in a Series D funding round. The round was co-led by Hamilton Bioventures and Alta Partners, and also included MPM Capital and Investor Growth Capital. Ceregene said the new funding will go towards its Phase 2b clinical study of its lead compound, targeted at treatment of Parkinson's disease. As part of the funding, Hamilton BioVentures' Kerry Dance joins the company's board. Separately, the firm said it has received an additional $733,437 as part of the Therapeutic Discovery Tax Credit program. More information »